Treatment-resistant depression is an important contributor to the global burden of depression. Antidepressant augmentation is a recommended treatment strategy for treatment-resistant patients, but outcomes remain poor. Identifying factors that are predictive of response to augmentation treatments may improve outcomes.
Aims:
This review aimed to synthesise the existing literature examining predictors of response to augmentation treatments in patients who had insufficiently responded to initial treatment.
Methods:
A systematic search was conducted identifying 2241 unique manuscripts. 24 examining predictors of outcome to pharmacological or psychological augmentation treatment were included in this review.
Results:
Atypical antipsychotics were the most frequently assessed treatment class (nine studies), closely followed by mood stabilisers (eight studies). Only one eligible psychological augmentation study was identified. Early response to treatment (week 2) was the best-supported predictor of subsequent treatment outcome, reported by six studies. Many predictor variables were only assessed by one report and others such as pre-treatment severity yielded contradictory results, both within and across treatment classes.
Conclusions:
This review highlights the importance of early response as a predictor of pharmacological augmentation outcome, with implications for both the monitoring and treatment of resistant unipolar patients. Further replication is needed across specific interventions to fully assess the generalisability of this finding. However, the clear lack of consistent evidence for other predictive factors both within and across treatments, and the scarce examination of psychological augmentation, demonstrates the need for much more research of a high quality if response prediction is to improve outcomes for patients with treatment-resistant depression.
AdliMBaethgeCHeinzA, et al. (2005) Is dose escalation of antidepressants a rational strategy after a medium–dose treatment has failed?Eur Arch Psychiatry Clin Neurosci255: 387–400.
2.
AgidOLererB (2003) Algorithm-based treatment of major depression in an outpatient clinic: Clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation. Int J Neuropsychopharmacol6: 41–49.
3.
ÁlvarezEPérez-SoláVPérez-BlancoJ, et al. (1997) Predicting outcome of lithium added to antidepressants in resistant depression. J Affect Disord42: 179–186.
4.
BarbeeJGConradEJJamhourNJ (2004) Aripiprazole augmentation in treatment-resistant depression. Ann Clin Psychiatry16: 189–194.
5.
BarbeeJGJamhourNJ (2002) Lamotrigine as an augmentation agent in treatment-resistant depression. J Clin Psychiatry63: 737–741.
6.
BarnicotKKatsakouCBhattiN, et al. (2012) Factors predicting the outcome of psychotherapy for borderline personality disorder: A systematic review. Clin Psychol Rev32: 400–412.
7.
BerlimMTTureckiG (2007) What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. Eur Neuropsychopharmacol17: 696–707.
8.
BermanRMFavaMThaseME, et al. (2009) Aripiprazole augmentation in major depressive disorder: A double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr14: 197–206.
9.
BermanRMMarcusRNSwaninkR, et al. (2007) The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry68: 843–853.
BschorTBaethgeCAdliM, et al. (2003a) Association between response to lithium augmentation and the combined DEX/CRH test in major depressive disorder. J Psychiatr Res37: 135–143.
12.
BschorTBaethgeCAdliM, et al. (2003b) Lithium augmentation increases post-dexamethasone cortisol in the dexamethasone suppression test in unipolar major depression. Depress Anxiety17: 43–48.
13.
BschorTBaethgeCAdliM, et al. (2003c) Hypothalamic-pituitary-thyroid system activity during lithium augmentation therapy in patients with unipolar major depression. J Psychiatry Neurosci28: 210–216.
14.
BschorTCanataBMüller-OerlinghausenB, et al. (2001) Predictors of response to lithium augmentation in tricyclic antidepressant-resistant depression. J Affect Disord64: 261–265.
CaseyDELaubmeierKKMarlerSV, et al. (2012) Efficacy of adjunctive aripiprazole in major depressive disorder: A pooled response quartile analysis and the predictive value of week 2 early response. Prim Care Companion CNS Disord14. pii: PCC.11m01251.
17.
CleareAParianteCYoungA, et al. (2015) Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British association for psychopharmacology guidelines. J Psychopharmacol29: 459–525.
18.
De CarloVCalatiRSerrettiA (2016) Socio-demographic and clinical predictors of non-response/non-remission in treatment resistant depressed patients: A systematic review. Psychiatry Res240(Suppl C): 421–430.
19.
DornseifBEDunlopSRPotvinJH, et al. (1989) Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol Bull25: 71–79.
20.
EllerTVasarVShlikJ, et al. (2009) Effects of bupropion augmentation on pro-inflammatory cytokines in escitalopram-resistant patients with major depressive disorder. J Psychopharmacol23: 854–858.
21.
FavaMRushAJAlpertJE, et al. (2008) Difference in treatment outcome in outpatients with anxious versus nonanxious depression: A STAR*D Report. Am J Psychiatry165: 342–351.
22.
FekaduADonocikJGCleareAJ (2018) Standardisation framework for the Maudsley staging method for treatment resistance in depression. BMC Psychiatry18: 100.
23.
FekaduAWoodersonSCMarkopouloK, et al. (2009) What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. J Affect Disord116: 4–11.
24.
FischerSMacareCCleareAJ (2017) Hypothalamic-pituitary-adrenal (HPA) axis functioning as predictor of antidepressant response–meta-analysis. Neurosci Biobehav Rev83: 200–211.
25.
GebaraMADiNapoliEAKasckowJ, et al. (2018) Specific depressive symptoms predict remission to aripiprazole augmentation in late-life treatment resistant depression. Int J Geriatr Psychiatry33: e330–e335.
26.
HoustonJPLauKArisV, et al. (2012) Association of common variations in the norepinephrine transporter gene with response to olanzapine-fluoxetine combination versus continued-fluoxetine treatment in patients with treatment-resistant depression: A candidate gene analysis. J Clin Psychiatry73: 878–885.
27.
IosifescuDVBoloNRNierenbergAA, et al. (2008) Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder. Biol Psychiatry63: 1127–1134.
28.
IsingMHorstmannSKloiberS, et al. (2007) Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression–a potential biomarker?Biol Psychiatry62: 47–54.
29.
JoffeRTLevittAJBagbyRM, et al. (1993) Predictors of response to lithium and triiodothyronine augmentation of antidepressants in tricyclic non-responders. Br J Psychiatry163: 574–578.
30.
KiltsCDWadeAGAndersenHF, et al. (2009) Baseline severity of depression predicts antidepressant drug response relative to escitalopram. Expert Opin Pharmacother10: 927–936.
31.
KornsteinSGSchneiderRK (2001) Clinical features of treatment-resistant depression. J Clin Psychiatry62(Suppl. 6): 18–25: 17.
32.
KrapohlEPatelHNewhouseS, et al. (2018) Multi-polygenic score approach to trait prediction. Mol Psychiatry23: 1368–1374.
33.
MarcusRNMcQuadeRDCarsonWH, et al. (2008) The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol28: 156–165.
34.
McIntyreRSGorwoodPThaseME, et al. (2015) Early symptom improvement as a predictor of response to extended release quetiapine in major depressive disorder. J Clin Psychopharmacol35: 706–710.
35.
MerkourisSSThomasSABrowningCJ, et al. (2016) Predictors of outcomes of psychological treatments for disordered gambling: A systematic review. Clin Psychol Rev48: 7–31.
36.
MoherDShamseerLClarkeM, et al. (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev4: 1.
37.
MuzinaDJChambersJSCamachoTA, et al. (2011) Adjunctive aripiprazole for depression: predictive value of early assessment. Am J Manag Care17: 793–801.
38.
National Institute for Health and Care Excellence (NICE) (2017) Depression in Adults: Treatment and Management. London: NICE.
39.
NuttDJBlierP (2016) Neuroscience-based nomenclature (NbN) for journal of psychopharmacology. J Psychopharmacol30: 413–415.
40.
ParianteCMLightmanSL (2008) The HPA axis in major depression: Classical theories and new developments. Trends Neurosci31: 464–468.
41.
PerlmanKBenrimohDIsraelS, et al. (2019) A systematic meta-review of predictors of antidepressant treatment outcome in major depressive disorder. J Affect Disord243: 503–515.
42.
RasgonNLinKWLinJ, et al. (2016) Telomere length as a predictor of response to Pioglitazone in patients with unremitted depression: A preliminary study. Transl Psychiatry6: e709.
43.
RizviSJGeraciJRavindranA, et al. (2014) Predictors of response to adjunctive osmotic-release methylphenidate or placebo in patients with major depressive disorder: Effects of apathy/anhedonia and fatigue. J Clin Psychopharmacol34: 755–759.
44.
RushAJTrivediMHWisniewskiSR, et al. (2006) Acute and longer-term outcomes in depressed outpatients requiring or several treatment steps: A STAR*D Report. Am J Psychiatry163: 1905–1917.
45.
SchafferAKreindlerDReisC, et al. (2013) Use of mental health telemetry to enhance identification and predictive value of early changes during augmentation treatment of major depression. J Clin Psychopharmacol33: 775–781.
46.
Scottish Intercollegiate Guidelines Network (2012) Methodology Checklist 2: Controlled Trials [Internet]. Available at: https://www.sign.ac.uk/checklists-and-notes.html (accessed 11 October 2018).
47.
SteffensDCNelsonJCEudiconeJM, et al. (2011) Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: A pooled subpopulation analysis. Int J Geriatr Psychiatry26: 564–572.
48.
StrawbridgeRArnoneDDaneseA, et al. (2015) Inflammation and clinical response to treatment in depression: A meta-analysis. Eur Neuropsychopharmacol25: 1532–1543.
49.
StrawbridgeRCarterBMarwoodL, et al. (2019) Augmentation therapies for treatment-resistant depression: Systematic review and meta-analysis. Br J Psychiatry214: 42–51.
50.
SzegediAJansenWTvan WilligenburgAPP, et al. (2009) Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: A meta-analysis including 6562 patients. J Clin Psychiatry70: 344–353.
51.
TakahashiMSuzukiMMuneokaK, et al. (2014) Personality traits as predictors for the outcome of lithium augmentation in treatment-resistant depression. Psychiatry Res220: 1144–1146.
52.
TaylorRMarwoodL, Rebecca Strawbridge, et al (2018) Predictors of response to treatment augmentation in patients with treatment resistant depression: A systematic review protocol. PROSPERO CRD42018091909. Available at: http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018091909.
53.
ThaseMERushAJ (1997) When at first you don’t succeed: Sequential strategies for antidepressant nonresponders. J Clin Psychiatry58(Suppl. 13): 23–29.
54.
TohenMCaseMTrivediMH, et al. (2010) Olanzapine/fluoxetine combination in patients with treatment-resistant depression: Rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J Clin Psychiatry71: 451–462.
55.
WilliamsLMDebattistaCDucheminAM, et al. (2016) Childhood trauma predicts antidepressant response in adults with major depression: Data from the randomized international study to predict optimized treatment for depression. Transl Psychiatry6: e799.
56.
WooYSBahkWMJeongJH, et al. (2013) Tianeptine combination for partial or non-response to selective serotonin re-uptake inhibitor monotherapy. Psychiatry Clin Neurosci67: 219–227.
YoshimuraSOkamotoYOnodaK, et al. (2014) Cognitive behavioral therapy for depression changes medial prefrontal and ventral anterior cingulate cortex activity associated with self-referential processing. Soc Cogn Affect Neurosci9: 487–493.
59.
ZhouXRavindranAVQinB, et al. (2015) Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: Systematic review and network meta-analysis. J Clin Psychiatry76: e487–e498.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
